Ambuja Cements Suspension of Sanghi Industries Equity Shares Effective April 06, 2026
Ambuja Cements has confirmed that, following the approval of the scheme of amalgamation by the National Company Law Tribunal, the equity…
Elgi Equipments Company Receives ESG Rating Score of 66
Elgi Equipments has been assigned an ESG rating of 66 by NSE Sustainability Ratings & Analytics Ltd. The assessment was conducted…
SBI Life Insurance Announces Leadership Changes in Business Strategy and Operations
SBI Life Insurance has announced a strategic shift in its leadership team, effective April 6, 2026. Mr. Santosh Chacko has been appointed as…
Prestige Estates Projects Limited GIC Reduces Stake via Open Market Sale
GIC Private Limited, acting on behalf of the Government of Singapore, has reduced its shareholding in Prestige Estates Projects Limited.…
Choice International Limited Appointment of Mr. Vimal Kumar Jain to Advisory Board
Choice International Limited has announced the appointment of Mr. Vimal Kumar Jain as a member of its Advisory Board. With over four decades…
PC Jeweller Reports Robust Q4 Performance and Strategic Expansion Initiatives
PC Jeweller Limited has announced a strong financial performance for Q4FY2026, achieving a standalone revenue growth of 32% year-on-year. For…
MedPlus Health Services Limited Compliance Report for the Quarter Ended March 31, 2026
MedPlus Health Services Limited has successfully fulfilled its quarterly compliance requirements. The company received formal confirmation…
Tata Motors Passenger Vehicles Limited Q4 Sales and Production Report Released
Tata Motors Passenger Vehicles Limited has released its performance data for the final quarter of the fiscal year (January to March 2026). The…
Grasim Industries Full Interest Payment Made on Non-Convertible Debentures
Grasim Industries has successfully completed the interest payment for its 6.99% Non-Convertible Debentures (NCDs). The total interest payout…
Aurobindo Pharma CuraTeQ Biologics Reports Positive Phase 3 Results for Omalizumab Biosimilar
Aurobindo Pharma’s subsidiary, CuraTeQ Biologics, has announced successful top-line results from its Phase 3 clinical study of BP11, a…